Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC boosted its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 148.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 469,988 shares of the company's stock after purchasing an additional 281,018 shares during the quarter. Geode Capital Management LLC owned about 1.74% of Alto Neuroscience worth $5,378,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of ANRO. Bank of New York Mellon Corp purchased a new position in Alto Neuroscience during the 2nd quarter valued at about $252,000. Rhumbline Advisers purchased a new position in Alto Neuroscience during the second quarter valued at approximately $113,000. TD Asset Management Inc bought a new position in Alto Neuroscience in the second quarter worth approximately $928,000. Bowie Capital Management LLC purchased a new stake in Alto Neuroscience during the second quarter worth $462,000. Finally, Federated Hermes Inc. boosted its position in Alto Neuroscience by 33.3% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock valued at $128,000 after acquiring an additional 3,000 shares in the last quarter.

Analyst Ratings Changes

Several research firms have recently commented on ANRO. Stifel Nicolaus reduced their price target on Alto Neuroscience from $32.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. RODMAN&RENSHAW lowered shares of Alto Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Rodman & Renshaw cut shares of Alto Neuroscience from a "buy" rating to a "neutral" rating in a research report on Wednesday, October 23rd. Finally, Wedbush downgraded Alto Neuroscience from an "outperform" rating to a "neutral" rating and dropped their target price for the stock from $29.00 to $4.00 in a research note on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Alto Neuroscience has a consensus rating of "Moderate Buy" and an average price target of $20.00.

Alto Neuroscience Stock Performance

Shares of ANRO traded up $0.23 during trading hours on Friday, reaching $4.61. 161,415 shares of the company traded hands, compared to its average volume of 252,407. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The business has a fifty day moving average price of $4.15 and a 200-day moving average price of $9.18. Alto Neuroscience, Inc. has a 12-month low of $3.56 and a 12-month high of $24.00.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.05. On average, sell-side analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.